Company Overview
| Stock Name | 北京市春立正達醫療器械股份有限公司 － Ｈ股 |
|---|---|
| Stock Code | 01858 |
| Company Full Name | 北京市春立正達醫療器械股份有限公司 － Ｈ股 |
| Industry | 醫療保健 |
| Principal Activities | 主要從事生產和銷售手術性植入器材、器械和相關產品。 |
| Listing Date | 2015-03-11 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市通州區通州經濟開發區南區鑫覓西二路10號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.clzd.com |
| Share Registrar | |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 13.88 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 115,689,800 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 14.3 |
|---|---|
| First Day Open | HK$ 14.08 |
| First Day Change | 3.03% |
| First Day Volume | 10167800.0 |
| First Day Turnover | 148959000.0 |
Use of Proceeds
| Use of Proceeds | 1、全球發售所得款項凈額約50.0%或約97.5百萬港元將用于發展大興新生產基地第一期，包括： 1、1 約20.0%或約39百萬港元用作興建新生產廠房及配套設施； 1、2 約30.0%或約58.5百萬港元用作就標準關節假體、先進個性化關節假體及脊柱產品之生產而購置及安裝生產設備及機器。當新生產線開始運作（目前預計將為2017年10月前后），我們的標準假體、先進個性化關節假體及脊柱產品最大設計年產能將分別增加約40,000套、5,000套及25,000套； 2、全球發售所得款項凈額約20.2%或約39.39百萬港元將用于研發活動，包括： 2、1 約12.0%或約23.4百萬港元用作發展大興新生產基地之研發中心； 2、2 約4.2%或約8.19百萬港元用作購置新的研發設施及設備； 2、3 約4.0%或7.8百萬港元用作擴大我們就開發新產品及改善產品之研發活動之范疇； 3、全球發售所得款項凈額約20.0%或約39百萬港元將用于擴闊我們的現有營銷及經銷網絡以提升我們的市場滲透范圍至涵蓋更多經銷商及醫院，并因而增加我們的市場份額，包括： 3、1 約8.5%或約16.575百萬港元用作于大興新生產基地及中國其他地區建立及發展營銷服務中心，以擴闊我們營銷服務的地域覆蓋范圍； 3、2 約6.0%或11.7百萬港元用作招聘負責營銷之員工，以鞏固我們與醫院及醫療機構之關系及加強醫療執業人員對我們產品的認識； 3、3 約5.5%或10.725百萬港元用作贊助并參與學術會議及研討會； 4、全球發售所得款項凈額約9.8%或約19.11百萬港元將用于營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
中国光大融资有限公司 CE ACE409
Overall Coordinators (1)
中国光大证券（香港）有限公司 CE AAW536
Joint Bookrunners (1)
中国光大证券（香港）有限公司 CE AAW536
Joint Lead Managers (1)
中国光大证券（香港）有限公司 CE AAW536
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | 史文玲 |
|---|---|
| Company Secretary | 葉沛森 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 史春寶及家族成員(54.42%);中信證券股份有限公司(5.14%) |
|---|
